野生类型心脏粉症的八十岁人群中的塔法米迪斯:国际队列研究

相关实验视频

Updated: Jun 14, 2026

09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.2K

Philippe Debonnaire¹, Karl Dujardin², Nicolas Verheyen³

¹Department of Cardiology, AZ Sint-Jan Brugge, Ruddershove 10, 8000 Bruges, Belgium.

European heart journal

|March 4, 2025

概括

塔法米迪斯治疗改善了老年野生类型的西氨基酸心肌病患者的存活率. 虽然年龄不会影响疗效,但八十多岁的死亡率仍然很高,特别是那些晚些时候被诊断出来的人.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
老年病的医生老年病的医生

背景情况:

野生类型的跨甲基氨基酸心肌病变 (ATTR-CM) 越来越多地被诊断为八代人.
随机临床试验往往低于这个老年人群.
关于八十多岁的ATTR-CM患者的自然过程和tafamidis治疗结果的数据有限.

研究的目的:

调查tafamidis治疗对现实世界80岁患者与野生类型ATTR-CM的所有原因死亡率的影响.
为了比较八十岁和非八十岁的结果与野生类型的ATTR-CM.
评估年龄和疾病阶段对塔法米迪斯治疗疗效的影响.

主要方法:

国际,多中心队列研究710连续野生型ATTR-CM患者.
平均随访时间为2.2±1.8年.
分析所有原因的死亡率,比较tafamidis治疗与未治疗的患者,包括倾向性得分匹配.

主要成果:

八代人 (≥80岁) 占该队列的58.5%.
在倾向性得分匹配后,塔法米迪斯治疗与整体队列 (HR=0.53) 和八岁以上人群 (HR=0.57) 的死亡率明显降低有关.
虽然tafamidis提高了生存率,但八十岁的患者仍然有较差的结果,特别是当治疗开始时年龄≥90岁或在国家氨基粉症中心阶段≥3.3时.

结论:

在现实世界中,tafamidis治疗在改善野生型ATTR-CM患者的存活率方面表现出有效性,无论年龄如何.
尽管治疗有好处,但在八十岁人口中,死亡率仍然相当高.
晚期的诊断或晚期的疾病阶段在八十岁的可能会限制治疗的好处.

关键词:

心脏氨基粉症症的心脏粉症心肌病是一种心肌病.死亡率死亡率死亡率八代人是指八代人的.塔法米迪斯 (Tafamidis) 是一个大家庭.转甲基素是一种转甲基素.

相关概念视频

01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...